| LYTIX BIOPHARMA NK -,10 |
| Norwegen |
| Gesundheit |
| NO0010405780 / A3CSAK |
| 6BG (Frankfurt) |
| FRA:6BG, ETR:6BG, 6BG:GR |
| - |
| https://www.lytixbiopharm.. |
|
Lytix Biopharma AS is a biotechnology company specializing in the development of novel cancer immunotherapies. The primary function of Lytix Biopharma is to design and advance therapies that harness the body’s immune system to recognize and eradica..
>Volltext.. |
| 71.18 Mio. EUR |
| 64.93 Mio. EUR |
| - |
| - |
| - |
| - |
| 0.19 Mio. EUR |
| 0.91 Mio. EUR |
| - |
| 3.9 |
| - |
| - |
| - |
| - |
| - |
| - |
| LYTIX BIOPHARMA, LYTIX BIO |
| 04.04.26 |
|